Antonio Díaz

The human gut microbiome is a complex adaptive ecosystem whose functions arise from interactions among microbial populations rather than from isolated taxa. Nevertheless, many microbiome-directed interventions still rely on administering individual strains, with limited consideration of the ecological processes governing community assembly, succession, and resilience. This review integrates evidence from microbial ecology, comparative genomics, systems biology, mechanistic physiology, and clinical microbiome research to propose a testable framework for ecologically engineering the human gut microbiome. Within this framework, selected spore-forming probiotics are hypothesized to function as transient pioneer organisms that modify intestinal physicochemical and metabolic conditions, thus facilitating the establishment and activity of functionally complementary microbial populations delivered through rationally designed synbiotic consortia. The proposed process comprises five stages: pioneer activity, niche remodeling, facilitated community assembly, functional-network stabilization, and the emergence of host-associated outcomes. Available genomic, physiological, and clinical observations support the biological plausibility of individual components of this model but do not yet demonstrate directed ecological succession as a complete causal process. Accordingly, the framework distinguishes established evidence from ecological inference and generates experimentally testable predictions of temporal niche modification, metabolic cross-feeding, functional redundancy, resilience after treatment withdrawal, and host metabolic responses. This ecological perspective shifts the objective of microbiome therapeutics from transient strain supplementation toward the predictable modulation of community trajectories, providing an experimental foundation for developing more resilient, mechanism-based interventions.

The human gut microbiome is a complex adaptive ecosystem whose functions arise from interactions among microbial populations rather than from isolated taxa. Nevertheless, many microbiome-directed interventions remain based on the administration of individual strains, with limited consideration of the ecological processes governing community assembly, succession, and resilience. This review integrates evidence from microbial ecology, comparative genomics, systems biology, mechanistic physiology, and clinical microbiome research to propose a testable framework for the ecological engineering of the human gut microbiome. Within this framework, selected spore-forming probiotics are hypothesized to function as transient pioneer organisms that modify intestinal physicochemical and metabolic conditions, thus facilitating the establishment and activity of functionally complementary microbial populations delivered through rationally designed synbiotic consortia. The proposed process comprises five stages: pioneer activity, niche remodeling, facilitated community assembly, functional-network stabilization, and the emergence of host-associated outcomes. Available genomic, physiological, and clinical observations support the biological plausibility of individual components of this model but do not yet demonstrate directed ecological succession as a complete causal process. Accordingly, the framework distinguishes established evidence from ecological inference and generates experimentally testable predictions of temporal niche modification, metabolic cross-feeding, functional redundancy, resilience after treatment withdrawal, and host metabolic responses. This ecological perspective shifts the objective of microbiome therapeutics from transient strain supplementation toward the predictable modulation of community trajectories, providing an experimental foundation for developing more resilient, mechanism-based interventions.

Microbiome-targeted interventions have shown promise for metabolic health, yet clinical evidence remains inconsistent, particularly across stages of metabolic disease. This study evaluated the metabolic effects, safety, and tolerability of EDC-HHA01, a microbiome-informed, non-pharmacologic intervention, in adults with prediabetes (PD) or Type 2 Diabetes (T2DM). In a randomized, double-blind, placebo-controlled clinical trial, participants received EDC-HHA01 or placebo for six months. The study was adequately powered (≥80%) for the primary endpoint. Outcomes included changes in glycated hemoglobin (HbA1c), indices of insulin resistance, markers of metabolic endotoxemia, safety-related laboratory parameters, and exploratory patient-reported measures. Analyses were stratified by metabolic status and background metformin use. In participants with PD, EDC-HHA01 supplementation was associated with a statistically and clinically meaningful reduction in HbA1c compared with placebo, supported by concordant improvements in fasting insulin, insulin resistance indices, and reductions in endotoxemia markers. In participants with T2DM, changes were directionally similar but attenuated and did not reach statistical significance. The intervention was well tolerated, with no serious adverse events, high adherence, and no clinically relevant adverse changes in renal or lipid parameters. Exploratory patient-reported outcomes indicated favorable acceptability but were not interpreted as efficacy endpoints. EDC-HHA01 was associated with biologically coherent, stage-dependent metabolic effects, most evident in PD. These findings support further investigation of microbiome-informed strategies as metabolic support in early-stage dysregulation.

Background: Microbiome-targeted interventions have shown promise for metabolic health, yet clinical evidence remains inconsistent, particularly across stages of metabolic disease. This study evaluated the metabolic effects, safety, and tolerability of EDC-HHA01, a microbiome-informed, non-pharmacologic intervention, in adults with prediabetes (PD) or Type 2 Diabetes (T2DM). Methods: In a randomized, double-blind, placebo-controlled clinical trial, participants received EDC-HHA01 or placebo for six months. The study was adequately powered (≥80%) for the primary endpoint. Outcomes included changes in glycated hemoglobin (HbA1c), indices of insulin resistance, markers of metabolic endotoxemia, safety-related laboratory parameters, and exploratory patient-reported measures. Analyses were stratified by metabolic status and background metformin use. Results: In participants with PD, EDC-HHA01 supplementation was associated with a statistically and clinically meaningful reduction in HbA1c compared with placebo, supported by concordant improvements in fasting insulin, insulin resistance indices, and reductions in endotoxemia markers. In participants with T2DM, changes were directionally similar but attenuated and did not reach statistical significance. The intervention was well tolerated, with no serious adverse events, high adherence, and no clinically relevant adverse changes in renal or lipid parameters. Exploratory patient-reported outcomes indicated favorable acceptability but were not interpreted as efficacy endpoints. Conclusions: EDC-HHA01 was associated with biologically coherent, stage-dependent metabolic effects, most evident in PD. These findings support further investigation of microbiome-informed strategies as metabolic support in early-stage dysregulation.

(1) Background: Heyndrickxia coagulans, a lactic acid-producing bacterium, displays characteristics of both Lactobacillus and Bacillus genera. Clinical evidence suggests its potential health benefits. This study evaluated the safety of H. coagulans AO1167B as a candidate probiotic supplement. (2) Methods: Strain identification was confirmed through morphological, cultural, and genomic analyses, including 16S RNA and whole genome sequencing to assess antimicrobial resistance and virulence factors. Phenotypic tests, such as disk diffusion for antimicrobial resistance, and safety assays for cytotoxicity and hemolytic activity, were conducted. In a phase I, double-blind, placebo-controlled clinical trial, healthy adults were randomized into H. coagulans AO1167B and placebo groups for 60 days. Daily capsule consumption was monitored through clinical and hematological evaluations, adverse event tracking, and health surveys. (3) Results: The genome of H. coagulans AO1167B revealed no concerning features. Disk diffusion tests showed no antimicrobial resistance. The strain exhibited no cytotoxic or hemolytic activity, indicating in vitro safety. No significant differences in clinical or hematological parameters were observed between groups. The most common adverse event, gas, diminished over time. (4) Conclusions: H. coagulans AO1167B demonstrates a suitable safety profile, genetic stability, and probiotic potential for gastrointestinal health, justifying further clinical research.

(1) Background: Alkalihalobacillus clausii AO1125 is a Gram-positive, motile, spore-forming bacterium with potential as a probiotic due to its broad-spectrum antimicrobial activity, inhibiting pathogens like Listeria monocytogenes, Staphylococcus aureus, and Clostridium difficile, as well as anti-rotavirus activity. Its resilience in gastrointestinal conditions suggests benefits for gut health. This study evaluates the safety and probiotic potential of A. clausii AO1125. (2) Methods: Genome annotation identified genes linked to probiotic traits such as stress resistance, gut colonization, immune modulation, and antimicrobial production. The genome was screened for antibiotic resistance genes using CARD, bacteriocin clusters using BAGEL4, and virulence factors via VFDB. Cytotoxicity was assessed on Vero cells and erythrocytes, and a Phase I, double-blind, placebo-controlled clinical trial was conducted with 99 healthy volunteers (50 AO1125, 49 placebo). (3) Results: Genomic analysis confirmed minimal antibiotic resistance genes and the absence of virulence factors, supporting safety. A. clausii AO1125 showed no pathogenicity, cytotoxicity, or hemolytic activity and was well-tolerated in clinical settings, with mild, transient abdominal gas as the most common adverse event. (4) Conclusions: The safety profile and genetic basis for probiotic and antimicrobial properties support A. clausii AO1125 as a promising probiotic candidate for gastrointestinal health, warranting further clinical research.